{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:35:53Z","timestamp":1786505753326,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clinthera.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T06:30:22Z","timestamp":1500964222000},"page":"1671-1679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM"],"prefix":"10.1016","volume":"39","author":[{"given":"\u00d3scar","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Theodore","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaulay","family":"Okwuokenye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing L.","family":"Marantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.06.012_bib1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7224\/1537-2073.2012-034","article-title":"Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the North American Research Committee on Multiple Sclerosis database","volume":"15","author":"Fox","year":"2013","journal-title":"International Journal of MS Care"},{"key":"10.1016\/j.clinthera.2017.06.012_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1212\/01.WNL.0000078885.05053.7D","article-title":"Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS","volume":"61","author":"Tremlett","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Eng. J. Med"},{"key":"10.1016\/j.clinthera.2017.06.012_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Eng. J. Med"},{"key":"10.1016\/j.clinthera.2017.06.012_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/acn3.148","article-title":"Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials","volume":"2","author":"Viglietta","year":"2015","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/01.wnl.0000171747.59767.5c","article-title":"Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study","volume":"65","author":"Kappos","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2017.06.012_bib8","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","article-title":"Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study","volume":"11","author":"Devonshire","year":"2012","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.msard.2013.11.006","volume":"3","author":"Khatri","year":"2014","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1016\/j.clinthera.2017.06.012_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-1331.2006.01273.x","article-title":"Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis","volume":"13","author":"Caon","year":"2006","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2011.03648.x","article-title":"Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response","volume":"19","author":"Rio","year":"2012","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.clinthera.2017.06.012_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","article-title":"Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate","volume":"17","author":"Phillips","year":"2015","journal-title":"International Journal of MS Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:05:32Z","timestamp":1575644732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817307658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0149291817307658"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}